August 27, 2014

BIO World

Calithera files to raise up to $80 million in IPO

Tumor metabolism and immunology specialist Calithera Biosciences Inc. on Tuesday revealed plans to raise up to $80 million in a yet-to-price initial public offering (IPO). The company will debut on Nasdaq under the symbol CALA and said it would use proceeds from the offering to advance CB-839, its phase I glutaminase inhibitor for triple-negative breast cancer and multiple myeloma as well as a preclinical arginase inhibitor.

To read more, visit:

By Michael Fitzhugh